Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Denver, CO 80202, United States February 22 - 25, 2026 Back

Tweet

Islatravir/Doravarine CROI 2026, Metabolics       Metabolics Islatravir-kidney, lipids, bone Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)   Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial   Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine   Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial   Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes   there were 3 studies reported at CROI 2026 and a publication that was made public right after presentation at CROI:   DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study - (02/26/26) this was published   Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase 3 Study - (02/23/26)   Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: 96-Week Update from a Blinded Phase 3 Study - (02/23/26)   Efficacy and Safety of Doravirine/Islatravir (100/0.25 mg) in Adults with HIV and Renal Impairment - (02/23/26)   Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) After ISL Dose Reduction From 0.75 mg: Week 48 Results From an Open-Label Phase 3 Study   Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1   Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in People Living With HIV - (10/23/25)   Population Pharmacokinetic Analysis of Islatravir and the Impact of Intrinsic Factors in Participants With HIV-1 - (10/23/25)   ------------------------   published- Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial - (02/26/26)